- Home
- OBK vs APLT Comparison
OBK vs APLT Comparison
Compare OBK & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OBK | APLT |
|---|---|---|
| Founded | 1912 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 18.0M |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | OBK | APLT |
|---|---|---|
| Price | $38.38 | $0.11 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 3 |
| Target Price | ★ $43.00 | $1.25 |
| AVG Volume (30 Days) | 143.3K | ★ 9.9M |
| Earning Date | 01-21-2026 | 11-13-2025 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $325,588,000.00 | $1,000,000.00 |
| Revenue This Year | $13.94 | $124.18 |
| Revenue Next Year | $6.04 | $66.67 |
| P/E Ratio | $20.11 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $28.80 | $0.10 |
| 52 Week High | $41.17 | $1.50 |
Technical Indicators
Market Signals| Indicator | OBK | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 58.34 | 25.98 |
| Support Level | $38.51 | $0.10 |
| Resistance Level | $38.92 | $0.13 |
| Average True Range (ATR) | 0.76 | 0.02 |
| MACD | -0.13 | 0.02 |
| Stochastic Oscillator | 41.74 | 7.66 |
Price Performance
Historical ComparisonAbout OBK Origin Bancorp Inc.
Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.